“At every stage of our existence we have been under the direct influence of microbes – remember, they were here first.”
Professor John F. Cryan

Our Mission

nuvoFIBR manufactures scientifically backed health products targeting beneficial bacteria in the human microbiome.

The microbiome has quickly become a new frontier in disease treatment and prevention. With compelling evidence published regularly, it is clear that maintaining a healthy balance of beneficial bacteria in the gut leads to better health outcomes over the long term.

Our motivation is to develop products and technologies which assist in the early detection of gut microbial imbalances and appropriate nutrition-based interventions to restore microbial balance and prevent disease.

Our Priorities

Prebiotics – the development of a range of prebiotic dietary supplements which support healthy gut function by promoting beneficial bacteria
Clinical Trials – advancing scientific understanding of the role of beneficial gut bacteria in the treatment of chronic disease, with a specific interest in depression
Technology – development of new technologies to assist in early detection of gut-related chronic disease with a specific interest in depression

Overview

Prebiotic fibre is used by the bacteria in our gut microbiome to create essential nutrients and vitamins that a human being cannot otherwise process.

Dietary fibre consumption is integral to our health. It impacts not only digestive health, but also lowers cholesterol, low blood sugar, and can assist in preventing certain diseases such as bowel cancer, diabetes and heart disease.

Product Offering

Supergut Everyday Fibre – prebiotic fibre supplement combining six plant fibres chosen for their demonstrated ability to promote beneficial bacteria in the gut. Launched July 2021 and currently for sale through www.supergutnutrition.com and selected pharmacies and health food stores in Melbourne. This is a food-grade supplement which is gluten, lactose and nut-free, 100% plant-based and vegan.

Clinical Trials

nuvoFIBR is scoping the following trials to be undertaken over the next 5 years:

Phase 1 clinical trial testing the potential benefit of prebiotic supplements in the treatment of clinical depression (specific to gut disease patients)
Pilot trial to determine the viability of breath-testing technology to aid in early diagnosis of depression and/or other gastrointestinal disorders
Pilot trial to determine the viability of gas-sensitive materials to aid in the early diagnosis of depression

Technology

nuvoFIBR is investigating technologies to understand their potential for early diagnosis of gastrointestinal diseases. These technologies are focused on providing a more palatable diagnostic tool than the faecal sampling required for DNA-analysis of bacterial species in the gut.

Breath testing technology
Gas identification technology
Nasal swab technology
Saliva analysis technology